Literature DB >> 2983150

A comparison of human breast cancer cell kinetics measured by flow cytometry and thymidine labeling.

R W McDivitt, K R Stone, R B Craig, J S Meyer.   

Abstract

Flow cytometric determination of tumor ploidy and S-phase fraction following collagenase dissociation and thymidine labeling was performed on 75 consecutive breast cancers. Estrogen and progesterone receptor levels and routine histologic examination also were obtained on each tumor. Cell viability following collagenase dissociation varied from 13 to 95% with a mean of 71%. Thirty-six tumors were diploid, four tetraploid, and four hypertetraploid, and the remainder had DNA indices between 1.1 and 1.9. There was no significant correlation between tumor ploidy and tumor size or estrogen receptor positivity or negativity. The percentage of cells in S-phase varied from 1.2 to 20.0% with a mean of 6.0% utilizing a rectilinear model for histogram analysis that integrated a 10-contiguous channel sample containing the lowest number of cells in S-phase (S-pFL). The mean S-pFL of diploid carcinomas (3.43%) was significantly lower than that of hyperdiploid carcinomas (8.38%). There was good correlation between S-phase fraction determined by thymidine-labeling index (TLI) and S-pFL (r = 0.772, p = 0.0001). S-pFL predicted whether a tumor would be above or below median TLI with an accuracy of 90.5%. Estrogen receptor-negative cancers tended to have higher TLIs and S-pFLs than estrogen receptor-positive cancers; however, there was no correlation between progesterone receptor positivity or negativity and TLI and S-pFL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983150

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  12 in total

Review 1.  Aneuploidy as a prognostic factor in breast cancer.

Authors:  A von Rosen
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Comparison of extent of disease and morphometric and DNA flow cytometric prognostic factors in invasive ductal breast cancer.

Authors:  A M Uyterlinde; N W Schipper; J P Baak
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

3.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

4.  Flow cytometric DNA analysis of thyroid carcinoma.

Authors:  A Tsuchiya; K Sekikawa; Y Ando; S Suzuki; I Kimijima; R Abe
Journal:  Jpn J Surg       Date:  1990-09

5.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

6.  Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer.

Authors:  D W Visscher; S Wykes; J Kubus; J D Crissman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  DNA ploidy and S-phase fraction in medullary carcinoma of the breast--a flow cytometric analysis using archival material.

Authors:  L Pedersen; J K Larsen; I J Christensen; A Lykkesfeldt; S Holck; T Schiødt
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  A general native-state method for determination of proliferation capacity of human normal and tumor tissues in vitro.

Authors:  R M Hoffman; K M Connors; A Z Meerson-Monosov; H Herrera; J H Price
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

9.  HER-2/neu oncogene expression and proliferation in breast cancers.

Authors:  S S Bacus; S G Ruby; D S Weinberg; D Chin; R Ortiz; J W Bacus
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

10.  Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G1 phase restriction point block.

Authors:  D L Tay; P S Bhathal; R M Fox
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.